The present application relates to a process for the preparation of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide represented by the following structural formula-1, which is referred to as Belumosudil and its intermediate preparation thereof.
Formula-1.
The present application also relates to novel crystalline forms of Belumosudil, its mesylate and its intermediate and preparation thereof
